ArticleVirus evolution2026
Identification and genomic characterization of BA.3.2: a highly divergent BA.3-related SARS-CoV-2 lineage from southern Africa.
Article in Virus evolution, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed.
- The conserved QTQTX motif in the SARS-CoV-2 spike protein is dispensable for cleavage and lung cell entry of the emerging variant BA.3.2.Journal of virology · 2026Article
- Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.Journal of virology · 2026Article
- NTD Remodeling in the SARS-CoV-2 BA.3.2 Variant May Influence Spike Stability and Immune Escape.Pathogens (Basel, Switzerland) · 2026Article
- Deep mutational scanning of recent SARS-CoV-2 variants highlights changing amino acid preferences within epistatic hotspot residues.PLoS pathogens · 2026Article
- Antigenic characterization of SARS-CoV-2 variants BA.3.2.1 and BA.3.2.2 in three animal models.bioRxiv : the preprint server for biology · 2026Article
- Predictive modeling of immune escape and antigenic grouping of SARS-CoV-2 variants.Journal of virology · 2026Article
- SARS-CoV-2 BA.3.2: epidemiological trends and implications for prophylactic antibodies.New microbes and new infections · 2026Article
- Early Detection and Surveillance of the SARS-CoV-2 Variant BA.3.2 - Worldwide, November 2024-February 2026.MMWR. Morbidity and mortality weekly report · 2026Article
- Evolution and viral properties of the SARS-CoV-2 BA.3.2 subvariant.Virus evolution · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In November 2024, a highly divergent BA.3-related severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineage, designated BA.3.2, was detected in South Africa, marking the first appearance of a BA.3-derived lineage in over 2 years. Phylogenetic reconstruction places BA.3.2 on an extended branch descending from ancestral BA.3, with no intermediate genomes detected, consistent with a prolonged period of unsampled or isolated evolution. Molecular clock analyses indicate accelerated divergence characteristic of a saltation event, whilst phylogeographic and demographic analyses point to a southern African origin followed by multiple independent exportations and evidence of ongoing global transmission. Relative to ancestral BA.3, BA.3.2 harbours 39 amino acid substitutions in the spike glycoprotein, two N-terminal domain deletions (Δ136-147 and Δ243-244), a four-residue insertion (ins214:ASDT), and a large deletion spanning ORF7a, ORF7b, and ORF8. The co-occurrence of D405N and R408S implies epistasis between these sites, whilst reversions R493Q and H505Y likely enhance ACE2 binding and antibody escape. Extensive remodelling across the spike, including loss of the C15-C136 disulphide bond and substitutions in the SD1 and SD2 domains, may influence spike stability, cleavage, and fusogenicity. The emergence and continued circulation of BA.3.2 underscores the ongoing potential for highly divergent SARS-CoV-2 variants to arise and spread globally. Despite its limited prevalence, the persistence of BA.3.2 alongside dominant lineages, together with evidence of more recent expansion, indicate that this lineage retains the potential to become of epidemiological concern under favourable conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.